| Host: |
Goat |
| Applications: |
Pep-ELISA/WB |
| Reactivity: |
Human/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-SPO11 (Internal) is suitable for use in ELISA and Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
WB-1-3µg/mlELISA-antibody detection limit dilution 1:16000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
SPO11 |
| Gene ID: |
23626 |
| Uniprot ID: |
SPO11_HUMAN |
| Immunogen Region: |
Internal |
| Accession Number: |
NP_036576.1; NP_937998.1 |
| Specificity: |
This antibody is expected to recognize both reported isoforms (NP_036576.1; NP_937998.1) |
| Immunogen Sequence: |
NTYATKRDIYYTDSQ |
| Function | Component of a topoisomerase 6 complex specifically required for meiotic recombination. Together with TOP6BL, mediates DNA cleavage that forms the double-strand breaks (DSB) that initiate meiotic recombination. The complex promotes relaxation of negative and positive supercoiled DNA and DNA decatenation through cleavage and ligation cycles. Essential for the phosphorylation of SMC3, HORMAD1 and HORMAD2. |
| Protein Name | Meiotic Recombination Protein Spo11Cancer/Testis Antigen 35Ct35 |
| Database Links | Reactome: R-HSA-912446 |
| Cellular Localisation | Nucleus |
| Alternative Antibody Names | Anti-Meiotic Recombination Protein Spo11 antibodyAnti-Cancer/Testis Antigen 35 antibodyAnti-Ct35 antibodyAnti-SPO11 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
